Crossover randomized multicentre clinical trial comparing the efficacy and tolerability of fixed-combinations of 0.1% brimonidine/0.5% timolol versus 1% dorzolamide/0.5% timolol as adjunctive therapies to prostaglandin analogues: Aibeta Crossover Study

被引：0
|
作者：
Inatani, Masaru [1 ]
机构：
[1] Fukui Daigaku Igakubu, Ophthalmol, Fukui, Japan
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4295
引用
收藏
页数：2
相关论文
共 22 条
  • [1] Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
    Masaru Inatani
    Yusuke Orii
    Kentaro Iwasaki
    Shogo Arimura
    Hiromi Sunagawa
    Minako Shiokawa
    Kenji Inoue
    Takuto Sakono
    Takato Sakono
    Rika Kuwamura
    Akiko Yoshida
    Junko Oi
    Yasuaki Kuwayama
    Kiyoshi Kano
    Noriaki Kido
    Akiko Matsuyama
    Mineo Ozaki
    Hideki Abe
    Chizuru Inoue
    Satoko Nakagawa
    Kunihiro Musashi
    Akiyasu Kanamori
    Jinhee Lee
    Shinichiro Otani
    Ryota Aoki
    Hirotaka Tanabe
    Shunsuke Nakakura
    Katsuyoshi Suzuki
    Takeshi Sagara
    Yoshiaki Saito
    Motoyasu Sameshima
    Mai Urahashi
    Fumika Watanabe-Kitamura
    Toshihiro Inoue
    Fumie Kagaya
    Yusuke Murai
    Sotaro Mori
    Kaori Ueda
    Takuji Kurimoto
    Yuko Yamada-Nakanishi
    Makoto Nakamura
    Takehiro Yamashita
    Sosuke Ishiyama
    Shinichi Manabe
    Keiko Takaki
    Ken Hayashi
    Akiko Ishida
    Aika Tsutsui
    Kaoru Manabe
    Masaki Tanito
    Advances in Therapy, 2023, 40 : 4074 - 4092
  • [2] Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
    Inatani, Masaru
    Orii, Yusuke
    Iwasaki, Kentaro
    Arimura, Shogo
    Sunagawa, Hiromi
    Shiokawa, Minako
    Inoue, Kenji
    Sakono, Takuto
    Sakono, Takato
    Kuwamura, Rika
    Yoshida, Akiko
    Oi, Junko
    Kuwayama, Yasuaki
    Kano, Kiyoshi
    Kido, Noriaki
    Matsuyama, Akiko
    Ozaki, Mineo
    Abe, Hideki
    Inoue, Chizuru
    Nakagawa, Satoko
    Musashi, Kunihiro
    Kanamori, Akiyasu
    Lee, Jinhee
    Otani, Shinichiro
    Aoki, Ryota
    Tanabe, Hirotaka
    Nakakura, Shunsuke
    Suzuki, Katsuyoshi
    Sagara, Takeshi
    Saito, Yoshiaki
    Sameshima, Motoyasu
    Urahashi, Mai
    Watanabe-Kitamura, Fumika
    Inoue, Toshihiro
    Kagaya, Fumie
    Murai, Yusuke
    Mori, Sotaro
    Ueda, Kaori
    Kurimoto, Takuji
    Yamada-Nakanishi, Yuko
    Nakamura, Makoto
    Yamashita, Takehiro
    Ishiyama, Sosuke
    Manabe, Shinichi
    Takaki, Keiko
    Hayashi, Ken
    Ishida, Akiko
    Tsutsui, Aika
    Manabe, Kaoru
    Tanito, Masaki
    ADVANCES IN THERAPY, 2023, 40 (09) : 4074 - 4092
  • [3] Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma
    Mizoue, Shiro
    Nitta, Koji
    Shirakashi, Motohiro
    Nitta, Akiyoshi
    Yamabayashi, Shigeki
    Kimura, Tairo
    Ueda, Toshihiko
    Takeda, Ryuji
    Matsumoto, Shun
    Yoshikawa, Keiji
    ADVANCES IN THERAPY, 2017, 34 (06) : 1438 - 1448
  • [4] Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma
    Shiro Mizoue
    Koji Nitta
    Motohiro Shirakashi
    Akiyoshi Nitta
    Shigeki Yamabayashi
    Tairo Kimura
    Toshihiko Ueda
    Ryuji Takeda
    Shun Matsumoto
    Keiji Yoshikawa
    Advances in Therapy, 2017, 34 : 1438 - 1448
  • [5] Erratum to: Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma
    Shiro Mizoue
    Koji Nitta
    Motohiro Shirakashi
    Akiyoshi Nitta
    Shigeki Yamabayashi
    Tairo Kimura
    Toshihiko Ueda
    Ryuji Takeda
    Shun Matsumoto
    Keiji Yoshikawa
    Advances in Therapy, 2017, 34 : 2179 - 2179
  • [6] Comparing the fixed combination dorzolamide-timolol (Cosopt®) to concomitant administration of 2% dorzolamide (Trusopt®) and 0.5% timolol -: a randomized controlled trial and a replacement study
    Francis, BA
    Du, LT
    Berke, S
    Ehrenhaus, M
    Minckler, DS
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2004, 29 (04) : 375 - 380
  • [7] Efficacy and Tolerability of Fixed Combination of Brimonidine 0.2%/Timolol 0.5% Compared with Fixed Combination of Dorzolamide 2%/Timolol 0.5% in the Treatment of Patients with Elevated Intraocular Pressure: A Meta-Analysis of Randomized Controlled Trials
    Budengeri, Patrick
    Cheng, Jin-Wei
    Cai, Ji-Ping
    Wei, Rui-Li
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (05) : 474 - 479
  • [8] Hypotensive Effect of Latanoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in NTG Patients: A Randomized, Multicenter, Crossover Clinical Trial
    Shoji, Takuhei
    Sato, Hiroki
    Mizukawa, Atsushi
    Hirota, Naoto
    Enoki, Toshio
    Kojima, Teruo
    Kanda, Takayuki
    Takeuchi, Masaru
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (09) : 6242 - 6247
  • [9] Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study
    Garcia-Lopez, Alfonso
    Paczka, Jose A.
    Jimenez-Roman, Jesus
    Hartleben, Curt
    BMC OPHTHALMOLOGY, 2014, 14
  • [10] Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study
    Alfonso García-López
    José A Paczka
    Jesús Jiménez-Román
    Curt Hartleben
    BMC Ophthalmology, 14
123